Results 1 to 10 of about 1,284,220 (297)

Complement Factor I Variants in Complement-Mediated Renal Diseases [PDF]

Frontiers in Immunology, 2022
C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS) are two rare diseases caused by dysregulated activity of the alternative pathway of complement secondary to the presence of genetic and/or acquired factors. Complement factor I (FI) is
Yuzhou Zhang, Renee X. Goodfellow, Nicolo Ghiringhelli Borsa, Hannah C. Dunlop, Stephen A. Presti, Nicole C. Meyer, Dingwu Shao, Sarah M. Roberts, Michael B. Jones, Gabriella R. Pitcher, Amanda O. Taylor, Carla M. Nester, Richard J. H. Smith   +12 more
doaj   +4 more sources

Heme Interferes With Complement Factor I-Dependent Regulation by Enhancing Alternative Pathway Activation [PDF]

Frontiers in Immunology, 2022
Hemolysis, as a result of disease or exposure to biomaterials, is characterized by excess amounts of cell-free heme intravascularly and consumption of the protective heme-scavenger proteins in plasma.
Alexandra Gerogianni, Alexandra Gerogianni, Jordan D. Dimitrov, Alessandra Zarantonello, Victoria Poillerat, Satheesh Chonat, Satheesh Chonat, Kerstin Sandholm, Karin E. McAdam, Kristina N. Ekdahl, Kristina N. Ekdahl, Kristina N. Ekdahl, Tom E. Mollnes, Tom E. Mollnes, Tom E. Mollnes, Camilla Mohlin, Camilla Mohlin, Lubka T. Roumenina, Per H. Nilsson, Per H. Nilsson, Per H. Nilsson   +20 more
doaj   +4 more sources

Cutaneous Vasculitis and Recurrent Infection Caused by Deficiency in Complement Factor I [PDF]

Frontiers in Immunology, 2018
Cutaneous leukocytoclastic vasculitis arises from immune complex deposition and dysregulated complement activation in small blood vessels. There are many causes, including dysregulated host response to infection, drug reactions, and various autoimmune ...
Sira Nanthapisal, Sira Nanthapisal, Despina Eleftheriou, Kimberly Gilmour, Valentina Leone, Radhika Ramnath, Ebun Omoyinmi, Ying Hong, Nigel Klein, Paul A. Brogan   +9 more
doaj   +6 more sources

Complement Factor I Mutation May Contribute to Development of Thrombotic Microangiopathy in Lupus Nephritis [PDF]

Frontiers in Medicine, 2021
Objective: Renal thrombotic microangiopathy (TMA) is associated with complement overactivation and poor outcome in patients with lupus nephritis (LN). The role of genetic makeup of complement system in these patients remains to be elucidated.Methods: The
Min-Hua Tseng, Min-Hua Tseng, Wen-Lang Fan, Hsuan Liu, Hsuan Liu, Hsuan Liu, Chia-Yu Yang, Chia-Yu Yang, Chia-Yu Yang, Chia-Yu Yang, Jhao-Jhuang Ding, Hwei-Jen Lee, Shih-Ming Huang, Shih-Hua Lin, Jing-Long Huang   +14 more
doaj   +4 more sources

Functional evaluation of complement factor I variants by immunoassays and SDS-PAGE [PDF]

Frontiers in Immunology, 2023
Factor I (FI) is an essential regulator of the complement system. Together with co-factors, FI degrades C3b, which inhibits further complement activation.
Alexandra Gerogianni, Alexandra Gerogianni, Laura M. Baas, Dick J. Sjöström, Dick J. Sjöström, Nicole C. A. J. van de Kar, Marit Pullen, Siem J. van de Peppel, Per H. Nilsson, Per H. Nilsson, Lambertus P. van den Heuvel, Lambertus P. van den Heuvel, Lambertus P. van den Heuvel, Lambertus P. van den Heuvel   +13 more
doaj   +2 more sources

A Candidate Prognostic Biomarker Complement Factor I Promotes Malignant Progression in Glioma [PDF]

Frontiers in Cell and Developmental Biology, 2021
Objectives: Glioma is the most common and aggressive type of primary central nervous system (CNS) tumor in adults and is associated with substantial mortality rates.
Xiaomin Cai, Wenjin Qiu, Mengshu Qian, Shuang Feng, Chenghao Peng, Jiale Zhang, Yi Wang, Yuhai Wang   +7 more
doaj   +2 more sources

Functional evaluation of rare variants in complement factor I using a minigene assay [PDF]

Frontiers in Immunology
The regulatory serine protease, complement factor I (FI), in conjunction with one of its cofactors (FH, C4BP, MCP, or CR1), plays an essential role in controlling complement activity through inactivation of C3b and C4b.
Cobey J. H. Donelson, Nicolo Ghiringhelli Borsa, Amanda O. Taylor, Richard J. H. Smith, Yuzhou Zhang   +4 more
doaj   +2 more sources

Rare Dysfunctional Complement Factor I Genetic Variants and Progression to Advanced Age-Related Macular Degeneration [PDF]

Ophthalmology Science, 2023
Purpose: To evaluate associations between rare dysfunctional complement factor I (CFI) genetic variant status and progression to advanced age-related macular degeneration (AAMD), geographic atrophy (GA), and neovascular disease (NV). Design: Prospective,
Johanna M. Seddon, MD, Bernard Rosner, PhD, Dikha De, MPH, Tianxiao Huan, PhD, Anuja Java, MD, John Atkinson, MD   +5 more
doaj   +2 more sources

Sequential Increase in Complement Factor I, iC3b, and Cells Expressing CD11b or CD14 in Cutaneous Vasculitis [PDF]

Analytical Cellular Pathology, 2022
Mast cells contribute to the pathogenesis of cutaneous vasculitis through complement C3 that is cleaved to C3b and then to iC3b by complement factor I. The receptor of iC3b, CD11b, is expressed on neutrophils and monocytes and CD14 on monocytes.
Dina Rahkola, Tiina Lipitsä, Hanna Siiskonen, Anita Naukkarinen, Ilkka T. Harvima   +4 more
doaj   +2 more sources

CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I [PDF]

Antibodies, 2013
The CD20 mAbs, rituximab (RTX) and ofatumumab (OFA), have been used with success in the clinic in the treatment of B cell malignancies. These mAbs can eliminate B cells only by utilizing the body’s immune effector mechanisms, and there is considerable ...
Margaret A. Lindorfer, Paul V. Beum, Ronald P. Taylor   +2 more
doaj   +2 more sources